CBPartners is a leading global healthcare strategy consulting firm

Thought Leadership

Are Current Reimbursement Options for Opioid Use Disorder DTx Causing a Barrier to Widespread Adoption in the USA?

CBPartners’ Digital Therapeutics and Health Technology Expertise Team investigates reimbursement for Opioid Use Disorder (OUD) DTx in the US.

Insulin Approval Pathways USA vs. EU

Historically there has been limited competition for biologic drugs resulting in fewer choices and higher prices for patients. This analysis explores insulin products in the USA and EU to compare the approval pathways.

ADUCANUMAB APPROVAL: Impact on Payers, Trials, and Trust

Despite surpassing the challenge of FDA approval, there are now a wide range of implications for health care access and coverage in the U.S for aducanumab, a treatment for Alzheimer’s Disease.

Cell and Gene Therapy Landscape: Challenges and Opportunities for Biotech and Investors

Explore themes from biotech and investors in the cell and gene therapy space, as well as future-facing cell and gene therapy trends, new developments in the space, as well as what’s next.

Assessing the Value of Non-Curative Cell and Gene Therapies

Some cell and gene therapies without a curative promise have shown encouraging results for patients with chronic disorders, however manufacturers need to carefully design a value strategy for their non-curative assets to ensure maximum access and uptake in their target markets.

Latest career opportunities

New York City, San Francisco, London
Summer Analyst (Internship)
Apply
New York City, San Francisco, London
Manager, Commercial Strategic Planning
Apply
New York City, San Francisco, London
Analyst
Apply